TherapeuticsMD (TXMD) Misses Q3 EPS by 2c

November 3, 2016 4:31 PM EDT
Get Alerts TXMD Hot Sheet
Trade TXMD Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

TherapeuticsMD (NYSE: TXMD) reported Q3 EPS of ($0.13), $0.02 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $5.53 million versus the consensus estimate of $5.76 million.

“We are making excellent progress this year advancing our pipeline and enhancing our commercial capabilities focused on women’s health. During the quarter, we successfully completed the submission of our NDA for TX-004HR as a novel treatment for moderate to severe dyspareunia, a symptom of VVA due to menopause, and we continued ongoing pre-commercialization activities for this important product,” said TherapeuticsMD CEO Robert G. Finizio. “We now eagerly await the topline data from our Replenish Trial for TX-001HR in the fourth quarter of 2016, our second novel hormone therapy program, which, if approved, would be the first and only FDA-approved bio-identical combination of estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms due to menopause.”

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings, Management Comments

Related Entities

Earnings

Add Your Comment